EXACT Sciences Corporation (EXAS) - Total Assets
Based on the latest financial reports, EXACT Sciences Corporation (EXAS) holds total assets worth $5.86 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
EXACT Sciences Corporation - Total Assets Trend (1998–2025)
This chart illustrates how EXACT Sciences Corporation's total assets have evolved over time, based on quarterly financial data. Also see how much is EXACT Sciences Corporation worth for the company's overall valuation and market capitalisation.
EXACT Sciences Corporation - Asset Composition Analysis
Current Asset Composition (December 2025)
EXACT Sciences Corporation's total assets of $5.86 Billion consist of 26.6% current assets and 73.5% non-current assets. Review EXACT Sciences Corporation debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.3% |
| Accounts Receivable | $298.65 Million | 5.1% |
| Inventory | $166.20 Million | 2.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $919.92 Million | 15.7% |
| Goodwill | $2.37 Billion | 40.4% |
Asset Composition Trend (1998–2025)
This chart illustrates how EXACT Sciences Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See EXACT Sciences Corporation (EXAS) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EXACT Sciences Corporation's current assets represent 26.6% of total assets in 2025, a decrease from 90.9% in 1998.
- Cash Position: Cash and equivalents constituted 16.3% of total assets in 2025, down from 90.9% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 55.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 40.4% of total assets.
EXACT Sciences Corporation Competitors by Total Assets
Key competitors of EXACT Sciences Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩335.22 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €88.84 Million |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
EXACT Sciences Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.23 | 2.15 | 2.82 |
| Quick Ratio | 1.97 | 1.92 | 2.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $788.41 Million | $839.24 Million | $1.15 Billion |
EXACT Sciences Corporation - Advanced Valuation Insights
This section examines the relationship between EXACT Sciences Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.22 |
| Latest Market Cap to Assets Ratio | 3.38 |
| Asset Growth Rate (YoY) | -1.1% |
| Total Assets | $5.86 Billion |
| Market Capitalization | $19.80 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values EXACT Sciences Corporation's assets at a significant premium (3.38x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: EXACT Sciences Corporation's assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for EXACT Sciences Corporation (1998–2025)
The table below shows the annual total assets of EXACT Sciences Corporation from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.86 Billion | -1.14% |
| 2024-12-31 | $5.93 Billion | -8.39% |
| 2023-12-31 | $6.47 Billion | +3.93% |
| 2022-12-31 | $6.23 Billion | -6.85% |
| 2021-12-31 | $6.68 Billion | +35.73% |
| 2020-12-31 | $4.93 Billion | +40.49% |
| 2019-12-31 | $3.51 Billion | +130.03% |
| 2018-12-31 | $1.52 Billion | +154.61% |
| 2017-12-31 | $598.56 Million | +58.75% |
| 2016-12-31 | $377.04 Million | +3.50% |
| 2015-12-31 | $364.30 Million | +16.90% |
| 2014-12-31 | $311.62 Million | +112.53% |
| 2013-12-31 | $146.63 Million | +30.78% |
| 2012-12-31 | $112.12 Million | +15.64% |
| 2011-12-31 | $96.95 Million | +0.45% |
| 2010-12-31 | $96.52 Million | +274.52% |
| 2009-12-31 | $25.77 Million | +336.93% |
| 2008-12-31 | $5.90 Million | -59.59% |
| 2007-12-31 | $14.60 Million | -38.85% |
| 2006-12-31 | $23.87 Million | -36.93% |
| 2005-12-31 | $37.84 Million | -32.55% |
| 2004-12-31 | $56.11 Million | +61.79% |
| 2003-12-31 | $34.68 Million | -30.76% |
| 2002-12-31 | $50.09 Million | -20.62% |
| 2001-12-31 | $63.10 Million | +117.15% |
| 2000-12-31 | $29.06 Million | +511.26% |
| 1999-12-31 | $4.75 Million | -51.03% |
| 1998-12-31 | $9.71 Million | -- |
About EXACT Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence S… Read more